Skip Navigation

European Heart Journal 2002 23(2):117-123; doi:10.1053/euhj.2001.2731
Copyright © 2002 by the European Society of Cardiology.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Mehta, S.R
Right arrow Articles by Yusuf, S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mehta, S.R
Right arrow Articles by Yusuf, S
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary intervention

S.R Mehtaa,b,f1, J.W Eikelboomb,c, H.-J Rupprechtd, B.S Lewise, M.K Natarajana,b, C Yib, J Pogueb and S Yusufa,b

a Division of Cardiology, Hamilton Health Sciences Corporation, McMaster University, Hamilton, Canada
b the Population Health Institute, McMaster University, Hamilton, Canada
c Department of Haematology, Royal Perth Hospital, Perth, Australia
d Klinikum der Johannes-Gutenberg-Universitat, Mainz, Germany
e Lady Davis Carmel Hospital, Haifa, Israel

revised April 3, 2001; accepted April 4, 2001

Abstract

Aims Although hirudin is superior to unfractionated heparin for prevention of death, myocardial infarction, or refractory ischaemia in patients with non-ST-elevation acute coronary syndrome, it is not clear whether hirudin is also of benefit in acute coronary syndrome patients undergoing early percutaneous coronary intervention.

Methods and Results In the OASIS 2 trial, 10141 patients with non-ST-elevation acute coronary syndrome were randomized to 72h of intravenous hirudin or unfractionated heparin. Percutaneous coronary intervention was performed at the discretion of the investigator. One hundred and seventeen patients underwent percutaneous coronary intervention within the first 72h (‘early percutaneous coronary intervention’). In patients undergoing early percutaneous coronary intervention, hirudin compared with unfractionated heparin was associated with a significantly lower incidence of death or myocardial infarction at 96h (6·4% vs 21·4%, OR 0·30; 95% CI: 0·10–0·88) and 35 days (6·4% vs 22·9%, OR 0·25; 95% CI: 0·07–0·86). In the unfractionated heparin group, death or myocardial infarction was significantly higher at 35 days in patients undergoing early percutaneous coronary intervention compared with those managed conservatively (22·9% vs 7·3%, OR 3·14, P<0·001) but this early percutaneous coronary intervention-related hazard was not observed in hirudin-treated patients (6·4% vs 6·8%, OR 0·94 P=1·0). A time-dependent covariate for percutaneous coronary intervention was not significant in a Cox regression model, suggesting a similar treatment benefit with hirudin before and after percutaneous coronary intervention. After adjustment for percutaneous coronary intervention propensity, the benefits of hirudin remained significant. There were three major bleeds in patients undergoing early percutaneous coronary intervention, all in patients randomized to hirudin.

Conclusion In patients with non-ST-elevation acute coronary syndrome undergoing early percutaneous coronary intervention, a direct thrombin inhibitor such as hirudin may be more effective than heparin in reducing the incidence of ischaemic complications.

Key Words: Hirudin, unfractionated heparin, coronary artery disease

f1 Correspondence: Dr Shamir R. Mehta, McMaster University Medical Center, 1200 Main Street West, HSC 3U5, Hamilton, Ontario, Canada L8N 3Z5.

References

  1. Yusuf S, Flather M, Pogue J. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. Lancet. 1998;352:507–514[CrossRef][ISI][Medline]
  2. Ellis SG, Roubin GS, King SB III. Angiographic and clinical predictors of acute closure after native vessel angioplasty. Circulation. 1988;77:372–379[Abstract/Free Full Text]
  3. Thel MC, Califf RM, Tardiff BE. Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT II). Am J Cardiol. 2000;85:427–434[CrossRef][ISI][Medline]
  4. Fuster V, Badimon L, Badimon JJ. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:242–250[ISI][Medline]
  5. Topol EJ. Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation. 1998;97:211–218[Free Full Text]
  6. Heras M, Chesebro JH, Penny. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin vs recombinant hirudin, a specific thrombin inhibitor. Circulation. 1989;79:657–665[Abstract/Free Full Text]
  7. Heras M, Chesebro JH, Webster MW. Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis. Circulation. 1990;82:1476–1484[Abstract/Free Full Text]
  8. Chesebro JH, Badimon L, Fuster V. Importance of antithrombin therapy during coronary angioplasty. J Am Coll Cardiol. 1991;17:96B–100B[Medline]
  9. Popma JJ, Weitz J, Bittl JA. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest. 1998;114:728S–741S[ISI][Medline]
  10. Boersma E, Akkerhuis KM, Theroux P. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation. 1999;100:2045–2048[Abstract/Free Full Text]
  11. Weitz JI, Hudoba M, Massel D. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385–391[ISI][Medline]
  12. Meyer BJ, Badimon JJ, Mailhac A. Inhibition of growth of thrombus on fresh mural thrombus. Targeting optimal therapy. Circulation. 1994;90:2432–2438[Abstract/Free Full Text]
  13. Meyer BJ, Badimon JJ, Chesebro JH. Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin. Comparison with heparin and aspirin. Circulation. 1998;97:681–685[Abstract/Free Full Text]
  14. Meyer BJ, Fernandez-Ortiz A, Mailhac A. Local delivery of r-hirudin by a double-balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty. Circulation. 1994;90:2474–2480[Abstract/Free Full Text]
  15. Lancet. 1999;353:429–438[CrossRef][ISI][Medline]
  16. Rosenbaum PR. Discussing hidden bias in observational studies. Ann Intern Med. 1991;115:901–905[CrossRef][ISI][Medline]
  17. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999;150:327–333[Abstract/Free Full Text]
  18. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265–2281[CrossRef][ISI][Medline]
  19. Kleiman NS, Lincoff AM, Flaker GC. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. Circulation. 2000;101:751–757[Abstract/Free Full Text]
  20. Serruys PW, Herrman JP, Simon R. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. N Engl J Med. 1995;333:757–763[Abstract/Free Full Text]
  21. Bittl JA, Strony J, Brinker JA. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med. 1995;333:764–769[Abstract/Free Full Text]
  22. Roe MT, Granger CB, Ohman EM. Hirudin significantly reduces ischemic events following coronary intervention for acute coronary syndromes. J Am Coll Cardiol. 2000;35:39A
  23. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation. 1998;97:251–256[Abstract/Free Full Text]
  24. N Engl J Med. 1998;338:1488–1497[Abstract/Free Full Text]
  25. Topol EJ. Evolution of improved antithrombotic and antiplatelet agents: genesis of the comparison of abciximab complications with hirulog (and back-up abciximab) events trial (CACHET). Am J Cardiol. 1998;82:63P–68P[CrossRef][ISI][Medline]
  26. Stone PH, Thompson B, Anderson HV. Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: the TIMI III registry. JAMA. 1996;275:1104–1112[Abstract]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
P. R. Sinnaeve, J. Simes, S. Yusuf, J. Garg, S. Mehta, J. Eikelboom, J. A. Bittl, P. Serruys, E. J. Topol, and C. B. Granger
Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention
Eur. Heart J., November 2, 2005; 26(22): 2396 - 2403.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
D.A. Vorchheimer and V. Fuster
Thrombin inhibitors in acute coronary artery disease
Eur. Heart J., August 1, 2002; 23(15): 1142 - 1144.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
H. Mehta and B. J. Meyer
r-Hirudin for percutaneous coronary interventions--time to reconsider?
Eur. Heart J., January 2, 2002; 23(2): 95 - 97.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Mehta, S.R
Right arrow Articles by Yusuf, S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mehta, S.R
Right arrow Articles by Yusuf, S
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?